Cellid Co Ltd

Cellid maintains a liquidity position with a current ratio of 0.83, indicating that its current liabilities exceed its current assets. The company's cash and equivalents amount to KRW 22,343,775,560, while its long-term debt stands at KRW 27,778,492,140, resulting in a negative net cash position. The price-to-book ratio of 1.37 suggests that the market values the company slightly above its book value. Profitability metrics show significant challenges, with a return on equity of -16.26% and a return on assets of -10.89%, both well below the typical performance of the biotechnology industry. The company reported a net loss of KRW 12,069,197,070 and an operating loss of KRW 12,230,373,080, highlighting the substantial financial pressures it faces. The company's revenue is concentrated in a single business segment focused on cancer therapeutic vaccines, with no disclosed geographic diversification in the provided data. This lack of diversification increases exposure to market and regulatory risks specific to the biotechnology sector and South Korea. Looking ahead, the company is projected to maintain a negative growth trajectory, with no positive revenue delta provided in the outlook. The capital expenditure of KRW -25,394,960,050 indicates ongoing investment in R&D, but the negative free cash flow of KRW -34,949,362,500 suggests that these investments are not yet generating positive cash returns. The risk assessment highlights a medium liquidity risk due to the negative net cash position and a low dilution risk, with no immediate pressure for equity issuance. The company's valuation adjustments and liquidity position suggest a cautious approach to capital structure management. Recent filings and transcripts have not disclosed any material events that would significantly alter the company's strategic direction or financial outlook.